The total duration of this study for each participant is approximately 28 weeks, which includes a screening period of 4 weeks, followed by a 24-week double blind placebo-controlled treatment period. At the end of the treatment period, all participants will have the option to enter a separate study, the blinded extension study
Patient Stories
October 19, 2023
When Iwona Bonney, PhD, was diagnosed with breast cancer in April 2022 she took the same deliberative and highly-researched approach to her care that she brings to her work as Clinical Research Coordinator in the Department of Anesthesiology and Perioperative Medicine.